Excerpt: "Among the chemokine receptors, CXCR4 is the most involved in cancer, as it is expressed in at least 23 different types of cancers .50Inhibition of CXCR4, i.e. with plerixafor , will impair the development of lung metastases.51In fact, the CXCR4/SDF-1 axis has become the hallmark of several metastatic cancers, thus justifying attempts, i.e. by CXCR4 antagonists, to stop metastases.

Plerixafor is already an FDA approved chemokine antagonist. Re: cancer. Is LL upstream or downstream of its MoA?

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6379795/